P925: Impact of Prior Treatment Exposure on the Effectiveness of Ixazomib-Lenalidomidedexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in Routine Clinical Practice (The Insure Study)

Simple item page
dc.contributor.authorLee, H.C.
dc.contributor.authorRamasamy, K.
dc.contributor.authorMacro, M.
dc.contributor.authorDavies, F.E.
dc.contributor.authorAbonour, R.
dc.contributor.authorvan Rhee, F.
dc.contributor.authorHungria, V.T.
dc.contributor.authorPuig, N.
dc.contributor.authorRen, K.
dc.contributor.authorSilar, J.
dc.contributor.authorEnwemadu, V.
dc.contributor.authorCherepanov, D.
dc.contributor.authorStull, D.M.
dc.contributor.authorLeleu, X.
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2023-08-14T11:04:34Z
dc.date.available2023-08-14T11:04:34Z
dc.date.issued2022-06-23
dc.description.abstractResults from INSURE, a pooled, global analysis of 3 observational studies, show that the effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) used to treat relapsed/refractory multiple myeloma (RRMM) in routine clinical practice is comparable to its efficacy seen in the TOURMALINE-MM1 trial (median progression-free survival [PFS], 19.9 vs 20.6 months [mos]), with no new safety concerns (Leleu ASH 2021 #2701). Data on effectiveness outcomes following retreatment with agents used in earlier lines of therapy (LoTs) are limited, but may be of particular value for MM pts previously treated with lenalidomide (LEN) or proteosome inhibitors (PIs).
dc.eprint.versionFinal published version
dc.identifier.citationLee HC, Ramasamy K, Macro M, et al. P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY). Hemasphere. 2022;6(Suppl ):815-816. Published 2022 Jun 23. doi:10.1097/01.HS9.0000846568.99304.59
dc.identifier.urihttps://hdl.handle.net/1805/34893
dc.language.isoen_US
dc.publisherWolters Kluwer
dc.relation.isversionof10.1097/01.HS9.0000846568.99304.59
dc.relation.journalHemaSphere
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourcePMC
dc.subjectIxazomib-lenalidomide-dexamethasone (IRd)
dc.subjectRelapsed/refractory multiple myeloma (RRMM)
dc.subjectLines of therapy (LoTs)
dc.subjectLenalidomide (LEN)
dc.subjectProteosome inhibitors (PIs
dc.titleP925: Impact of Prior Treatment Exposure on the Effectiveness of Ixazomib-Lenalidomidedexamethasone in Relapsed/Refractory Multiple Myeloma Patients Treated in Routine Clinical Practice (The Insure Study)
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
hs9-6-0815.pdf
Size:
211.57 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works